Health economics is the study of how societies allocate limited resources to improve health. It covers everything from whether a new drug is worth its price tag to why the United States spends far more on healthcare than other wealthy nations without consistently better results. At its core, the field asks a deceptively simple question: how do we get the most health out of every dollar spent?
That question matters because healthcare budgets are finite, but the demand for medical care is practically limitless. New treatments, aging populations, and chronic diseases all compete for the same pool of money. Health economics provides the tools to make those trade-offs visible and, ideally, fairer.
Why Healthcare Doesn’t Follow Normal Market Rules
Most products follow basic supply-and-demand logic. You compare prices, choose what you can afford, and walk away if the deal isn’t right. Healthcare breaks almost every one of those rules, and understanding why is the starting point of health economics.
The biggest issue is information asymmetry. Your doctor knows far more about your illness and treatment options than you do. You’re relying on someone who is simultaneously diagnosing your problem and selling you the solution. If a physician owns a lab or imaging equipment, the profit motive can lead to more tests than necessary, a phenomenon economists call “supplier-induced demand.” In no other market does the seller have this much power to shape what the buyer purchases.
Insurance creates its own distortions. People with coverage tend to use more healthcare and may take fewer precautions to stay healthy, since they know the insurer picks up much of the tab. Economists call this moral hazard. Insurance companies fight it with co-payments, deductibles, and gatekeepers who monitor access. On the flip side, adverse selection means that people in poor health are the most motivated to buy insurance, driving up costs for everyone. If premiums rise too high, healthy people drop out, leaving only the sickest customers and threatening the viability of the insurance market altogether.
These failures explain why no country relies on a purely free market for healthcare. Every system involves some combination of government regulation, public funding, or mandated insurance to compensate for the ways healthcare defies ordinary economics.
How Countries Pay for Healthcare
Health economists study three broad models that countries use to fund medical care, though most real-world systems blend elements of all three.
The Beveridge model, named after the architect of Britain’s National Health Service, funds healthcare through general tax revenue. The government owns many hospitals and employs many providers directly. Citizens pay nothing at the point of care. The Bismarck model, common in Germany and France, uses payroll-funded insurance. Employers and employees split the cost, and unlike private American insurers, Bismarck-style plans are nonprofit and must cover all citizens. The National Health Insurance model, used in Canada and Taiwan, combines private-sector hospitals and doctors with a single government-run insurance program funded by taxes or premiums. Administrative costs tend to be lower than in systems with multiple competing insurers.
Each model handles the tension between access, cost, and quality differently. Beveridge systems keep costs low but can produce long wait times. Bismarck systems offer more choice but require robust regulation to prevent cherry-picking of healthy patients. National health insurance models control spending through caps on which services they cover or by requiring patients to wait for non-urgent care.
Measuring Whether a Treatment Is Worth It
One of the most practical tools in health economics is economic evaluation: a structured way to compare what a treatment costs against the health it delivers. Governments and insurers use these evaluations every day to decide which drugs, devices, and procedures to cover.
Cost-effectiveness analysis compares costs to a single health outcome measured in natural units, like years of life saved or points of blood pressure reduced. It works well when you’re choosing between two treatments for the same condition. Its limitation is that it can’t easily compare a cancer drug to a heart surgery, because the outcomes are measured in completely different units.
Cost-utility analysis solves that problem by converting all health gains into a single currency called the quality-adjusted life year, or QALY. A QALY combines how long you live with how well you live. One year in perfect health equals one QALY. One year with a serious disability might count as half a QALY. Because every treatment’s benefit is expressed in the same unit, decision-makers can compare a diabetes medication against a hip replacement and ask which delivers more health per dollar.
A related measure, the disability-adjusted life year (DALY), works in the opposite direction. Instead of counting health gained, it counts health lost to disease and early death. DALYs are more common in global public health, where researchers track the total burden of diseases across populations. QALYs are more common in decisions about individual treatments. The two measures use different assumptions about how to weight age and disability, but both serve the same purpose: putting a number on health so it can be weighed against cost.
Cost-per-QALY Thresholds
Once you can measure health in QALYs, the next question is: how much is one QALY worth? Countries answer this by setting thresholds. In the UK, the National Institute for Health and Care Excellence (NICE) currently considers treatments cost-effective if they fall within a range of £20,000 to £30,000 per QALY gained. Starting in April 2026, NICE will raise that range to £25,000 to £35,000 per QALY, partly to create a more attractive environment for pharmaceutical companies bringing new drugs to the UK market.
These thresholds aren’t absolute cutoffs. A treatment for a rare disease or one that addresses a condition with no existing options may be approved even if it exceeds the range. But the numbers provide a benchmark, a way to ensure that money spent on one treatment isn’t silently taking resources away from another treatment that could help more people.
Health Technology Assessment
The process that puts these evaluations into practice is called health technology assessment, or HTA. When a new drug receives regulatory approval (meaning it’s been proven safe and effective), it still has to pass an economic review before a national health system agrees to pay for it. HTA agencies evaluate comparative effectiveness against existing treatments, the strength of the clinical evidence, the budget impact, and cost-effectiveness.
The timeline varies by country. In Germany, the Federal Joint Committee completes a benefit assessment within three months of market authorization, publishes it for public comment, and issues a binding resolution within another three months. Italy’s medicines agency evaluates new high-cost drugs on three criteria: unmet medical need, clinical added value, and the robustness of evidence supporting both. These assessments directly shape what patients can access and at what price, making HTA one of the most consequential applications of health economics.
Fee-for-Service vs. Value-Based Care
Health economics also shapes how doctors and hospitals get paid, which in turn shapes the care you receive. The traditional model is fee-for-service: providers bill for each test, visit, and procedure. The more they do, the more they earn. This creates a natural incentive to do more, regardless of whether it improves your health.
Value-based care flips that incentive. Instead of paying for volume, insurers and government programs reward providers for keeping patients healthy and out of the hospital. The focus shifts to preventing chronic diseases like diabetes and heart failure, reducing complications, and improving long-term outcomes. Under some value-based models, hospitals that fail to meet quality benchmarks face financial penalties, while those that perform well receive bonus payments drawn from the savings. The logic is straightforward: spending more on prevention and ongoing management of chronic conditions costs less in the long run than paying for repeated emergency hospitalizations.
Efficiency and Equity
Two concepts sit at the heart of nearly every debate in health economics. Efficiency asks whether we’re getting the maximum health benefit from the resources we spend. Equity asks whether those benefits are distributed fairly.
These goals often pull in different directions. The most efficient use of money might be to fund treatments that help the largest number of people, but that could leave patients with rare diseases without options. Spending more on preventive care in wealthy neighborhoods might produce better measurable outcomes than spending the same amount in underserved communities, but most people would consider that unfair.
Health economists frame these tensions through models of distributive justice. A utilitarian approach maximizes total health across the population. An egalitarian approach prioritizes equal access regardless of ability to pay. A libertarian approach minimizes government intervention and lets individuals choose. Most real health systems combine these philosophies, and the mix reflects each society’s values. Reaching agreement on that mix is, as researchers have noted, critical to avoiding inequitable decisions, particularly in insurance-based systems where the rules determine who gets covered and at what cost.
Behavioral Economics and Health Choices
A newer branch of the field applies behavioral economics to healthcare. The core insight is that people don’t always make rational decisions about their health. They procrastinate on screenings, skip medications, overeat, and underestimate risk. Rather than simply telling people to make better choices, behavioral economists design environments that make the healthier choice easier.
These interventions, often called “nudges,” alter how options are presented without removing any choices. Making organ donation the default option (requiring people to opt out rather than opt in) dramatically increases donation rates. Placing healthier food at eye level in a cafeteria increases consumption without banning anything. Sending text reminders for medication refills improves adherence. The results aren’t always dramatic. A study testing whether altruistically framed messages could improve compliance with COVID-19 prevention measures among university students found no statistically significant effect compared to a control group. Nudges work best when the barrier to action is friction or forgetfulness, not deep-seated resistance.
Health economics, in the end, is the discipline that connects clinical medicine to the real-world constraints of money, politics, and human behavior. It doesn’t replace medical science. It asks what we can afford, who benefits, who pays, and whether we could do better.